TWST
Twist Bioscience CorporationNASDAQHealthcare$50.21+1.35%ClosedMarket Cap: $3.08B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
6.85
P/S
8.01
EV/EBITDA
-62.02
DCF Value
$-63.61
FCF Yield
-2.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
51.6%
Operating Margin
-34.4%
Net Margin
-19.6%
ROE
-16.6%
ROA
-12.0%
ROIC
-23.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 2026 | $103.7M | 52.0% | $-32.9M | $-30.5M | $-0.50 | — |
| Q4 2025 | $99.0M | 51.3% | $-29.9M | $-27.1M | $-0.45 | — |
| FY 2025 | $376.6M | 50.7% | $-136.3M | $-77.7M | $-1.30 | — |
| Q3 2025 | $96.1M | 53.4% | $-30.1M | $20.4M | $0.33 | — |
| Q2 2025 | $92.8M | 49.6% | $-41.6M | $-39.3M | $-0.66 | — |
| Q1 2025 | $88.7M | 48.3% | $-34.6M | $-31.6M | $-0.53 | — |
| Q4 2024 | $84.7M | 45.1% | $-36.0M | $-34.7M | $-0.60 | — |
| FY 2024 | $313.0M | 42.6% | $-220.8M | $-208.7M | $-3.60 | — |
| Q3 2024 | $81.5M | 43.3% | $-88.9M | $-85.6M | $-1.47 | — |
| Q2 2024 | $75.3M | 41.0% | $-48.9M | $-45.5M | $-0.79 | — |
| Q1 2024 | $71.5M | 40.5% | $-47.0M | $-43.0M | $-0.75 | — |
| Q4 2023 | $66.9M | 36.6% | $-50.1M | $-46.2M | $-0.81 | — |